IDWeek 2020: Physicians Taking a Hit in the Wallet by COVID-19
To evaluate the impacts of COVID-19—such as job loss, increased work hours, and the compensation...
Read More
Month: October 2020
IDWeek 2020: Acute HIV Cases Discovered Upon COVID-19 Screening
Although evidence indicates that undiagnosed cases of HIV are often found during routine screening...
Read More
IDWeek 2020: Dr. Fauci “Cautiously Optimistic” for COVID-19 Vaccine by Year’s End
Anthony Fauci, MD, said during a presentation at IDWeek that he is “cautiously optimistic” that a...
Read More
IDWeek 2020: Multidisciplinary Approach Curbs Opioid Use in Patients With IV Drug Use- Associated Infections
In 2018, University of Kentucky (UK) HealthCare reported 400 cases of endocarditis, of which 73%...
Read More
IDWeek 2020: Device Eliminates Blood Culture Contamination
Lucy S. Tompkins, MD, PhD, reported zero blood culture contamination events (0.0% contamination...
Read More
ACEP20: Violence Protection in the ED
The best strategy for addressing extreme violence, including a shooter, in the ED is preparation...
Read More
ACEP20: Advice on Treating Genitourinary Emergencies
In a presentation from Lauren Westafer, DO, MPH, MS, advised emergency physicians to not treat...
Read MoreAround the Corner: ACR Convergence 2020
ACR Convergence 2020, the world’s premier virtual rheumatology experience, is happening online, November 5 – 9. The fully virtual meeting is where rheumatology can collaborate, celebrate, innovate, and learn. During ACR...
Read More
ACEP20: Learning From EMS Use By LA’s Homeless Population
Recent estimates suggest 60,000 or Los Angeles’s 4 million residents are homeless, including a...
Read More
ACEP20: Reversal Agent Helps Stop Anti-Factor Xa-Related Bleeds
Research indicates that trauma among patients on anti-factor Xa drugs can produce life-threatening...
Read More
ACEP20: Despite Increased Stress Due to COVID-19, Nearly Half of ED Physicians Fear Seeking Mental Healthcare
A joint poll from ACEP and Morning Consult was conducted between October 7-October 13, 2020 among...
Read MoreNovel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues
In arthritis and other autoimmune disorders, chronic inflammation is mediated primarily by pro-inflammatory reactive macrophages. Systemic administration of anti-inflammatory agents does not selectively target the affected...
Read MoreNew Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
New data from the global Phase 2 clinical trial of mavrilimumab in giant cell arteritis (GCA) will be presented at the late-breaking abstracts session during the American College of Rheumatology (ACR) Convergence 2020....
Read MoreLong-Term Safety and Efficacy of Upadacitinib in RA and PsA
A body of research will be presented at this year’s ACR meeting in the hopes of demonstrating the potential for upadacitinib and adalimumab to play a significant role in the treatment of rheumatic diseases. Data evaluating...
Read MoreSustained Improvements of PsA at 1-Year with Apremilast
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast...
Read More
Untargeted metabolomics yields insight into ALS disease mechanisms
The study was done to identify dysregulated metabolic pathways in ALS versus control participants...
Read More
Inside minds, beneath diseases: social cognition in amyotrophic lateral sclerosis-frontotemporal spectrum disorder
This study was done to compare social cognition performance between patients with ALS and patients...
Read More
Pallidal deep brain stimulation in primary Meige syndrome: clinical outcomes and psychiatric features
The study was done to check the efficacy and safety of bilateral GPi-DBS in refractory MS and...
Read More
Deep brain stimulation of the subthalamic nucleus in obsessive–compulsives disorders
OCD is a major cause of disability and impairment of quality of life. 10% of patients are reported...
Read More
Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
Approximately 15%–20% of patients with GBS are unable to walk independently at 6 months from the...
Read More